Market News — Tuesday, July 21, 2026
News highlights with AI-explained potential impact from our daily market analysis.
AbbVie’s post-Humira story is still working
AbbVie’s latest figures show a large, profitable business: $56.33 billion in 2025 revenue, $4.85 in adjusted EPS, and a $1.64 quarterly dividend. Growth from Skyrizi and Rinvoq suggests the company is replacing older revenue with newer products.
Potential Impact: Investors looking for dependable large-cap healthcare names may see this as a sign that the business remains durable and income-friendly.
Aterian is simplifying, but shareholders should watch dilution risk
Aterian repaid and terminated its credit agreement and signed a CVR arrangement to distribute proceeds from asset and stock sales. But it also filed a prospectus for resale of up to 6.74 million shares, which can weigh on sentiment.
Potential Impact: The capital structure may become cleaner, but extra share supply can pressure the stock and make the recovery story harder.
Western Midstream’s yield looks attractive, but coverage is the issue
The company declared a $0.93 quarterly dividend, or 8.0% annualized yield, but its payout ratio is 103.0%. That means the dividend is not fully covered by earnings right now.
Potential Impact: Income investors may be drawn to the yield, but they should pay close attention to whether cash flow can sustain it.
Nvidia and Broadcom remain favored after the tech pullback
Morgan Stanley sees Nvidia and Broadcom as strong value ideas among chip stocks, and says the long-term AI infrastructure spending trend is still intact.
Potential Impact: The market may be using the pullback to separate durable businesses from speculative ones, which could create opportunities for patient investors.
Veritone’s legal overhang is a reminder to trust the numbers
A class action filing alleges false or misleading statements and misclassified revenue and costs. Even without a final outcome, such allegations can damage confidence.
Potential Impact: This may keep investors cautious and demand a bigger margin of safety before committing capital.
Raymond James enters earnings with momentum
Analysts expect 14% year-on-year revenue growth, and the stock has already risen 7.5% over the last month after beating revenue and EPS estimates last quarter.
Potential Impact: If results are strong again, the market may continue to reward the stock; if not, expectations could be the main risk.